Handelsavisen
prelaunch
Companies ›Healthcare ›002566.SZ
00
002566.SZ — Shenzhen Stock Exchange Pharmaceuticals

002566.Sz

¥17,69
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
5,9B CNY
P/E
—
EV / Rev
—
Div yield
1,20 %
Op margin
4,8 %
ROE
1,3 %
Net margin
4,5 %
Debt / equity
0,20
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
1,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 002566.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 002566.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.2, indicating a low reliance on debt financing. Its liquidity position is characterized as medium, with a current ratio of 6.24, suggesting strong short-term liquidity. However, the company's net cash position is negative after subtracting total debt, which may signal potential liquidity constraints.

    Profitability metrics show a return on equity (ROE) of 1.3% and a return on assets (ROA) of 0.98%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's gross profit margin is 73.6%, which is relatively high, but its operating margin is only 4.8%, indicating significant operating expenses relative to revenue.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher operational and market risks. The company's revenue concentration in a single segment suggests that its performance is highly dependent on the success of that segment.

    The company's growth trajectory is not clearly defined, as there are no specific numeric deltas provided for the current or next fiscal year. However, the company's operating cash flow of 98.7 million CNY and free cash flow of 12.4 million CNY suggest some level of operational efficiency. The capital expenditure of -13.6 million CNY indicates a reduction in capital spending, which may be a strategic move to preserve cash.

    The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints. The company's dilution potential is low, with no significant dilution sources identified in the available data.

    Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance. The company's financial statements and disclosures are consistent with its classification in the pharmaceuticals industry.

    Key takeaways
    • The company has a low debt-to-equity ratio, indicating a conservative capital structure.
    • The company's profitability metrics are below industry norms, suggesting room for improvement.
    • The company's revenue is concentrated in a single segment, increasing operational risk.
    • The company's liquidity position is medium, with a current ratio of 6.24.
    • The company's net cash position is negative after subtracting total debt, indicating potential liquidity constraints.
    • The company's capital expenditure is negative, suggesting a reduction in capital spending.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥17,69
    Market cap
    ¥2.43B
    Enterprise valueⓘ
    ¥2.88B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    29.2x
    P / Bⓘ
    1.1x
    P / Tangible bookⓘ
    1.1x
    Tangible book
    ¥2.23B
    Net cashⓘ
    -¥452.6M
    Current ratioⓘ
    6.2
    Debt / equityⓘ
    0.2
    ROAⓘ
    1.0%
    ROEⓘ
    1.3%
    Cash conversionⓘ
    340.0%
    CapEx / revenueⓘ
    -2.1%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin4,8 %Below median
    Net Margin4,5 %Above median
    ROE1,3 %Below median
    Capex / Rev-2,1 %Above median
    D/E0,20Below median
    Cash Conv3,40Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 002566.SZ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    002566.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    What changed

    4 tracked-field change(s) detected vs prior analysis; max severity: medium.

    • Dilution risk— → lowlow
    • Liquidity risk— → mediumlow
    • Activity— → Pharmaceuticalsmedium
    • Economic sector— → Healthcaremedium
    vs prior analysis today
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage